PharmAsia News Notable Notes: China’s Outsourcing Costs Vs. Growth Potential
This article was originally published in PharmAsia News
Analysts' views on the costs associated with outsourcing research to China remains mixed, but concerns regarding fluctuations in costs are minimized by opportunity for growth in China, according to Baird analyst Eric Coldwell
You may also be interested in...
Looking to increase global market share, Pfizer has established a business unit devoted to oncology within its worldwide pharmaceutical group, in part, to strengthen research investment on cancers common in Asia, including liver, esophagus and nasopharynx
SHANGHAI - Charles River Laboratories is expanding its operations in China with Western-standard discovery and good laboratory practice services that will enable it to conduct studies suitable to submit to regulators in the U.S., Europe and China, the company said Feb 20
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).